The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

By Zachary Stieber Contributing Writer Sarepta Therapeutics will not agree to a regulatory request to pause shipments of a ...

U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S. compan ...

That helped offset a 5.4% drop for Sarepta Therapeutics ... asked the company to voluntarily stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, due to safety concerns.

Real-time index price for Nasdaq Composite (NASX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy ...